ImmuCell Corporation - Common Stock (ICCC)
Healthcare › In Vitro & In Vivo Diagnostic Substances
Price History
Feb 9, 2026 — May 9, 2026Investment Snapshot
- Trading 180% above Graham Number — above intrinsic value estimate
- Piotroski F-Score 7/9 — financially strong with improving fundamentals
- ROE of 4.1% — below-average profitability
ImmuCell Corporation - Common Stock (ICCC) is a Healthcare company operating in In Vitro & In Vivo Diagnostic Substances, listed on the NASDAQ , with a market capitalisation of $73 million . Key value metrics: P/E ratio 65.8, P/B ratio 2.69, Piotroski F-Score 7 out of 9 (strong financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
ImmuCell Corporation - Common Stock — Fundamental Analysis Summary
ImmuCell Corporation - Common Stock (ICCC) is currently trading 180% above its Graham Number of $2.87, suggesting the market price exceeds Benjamin Graham's intrinsic value estimate. The stock carries an elevated trailing P/E ratio of 65.8x.
On financial health, ICCC shows a strong Piotroski F-Score of 7/9, indicating improving fundamentals across profitability, leverage, and efficiency, and modest return on equity of 4.1% (sector average: -20.6%), and manageable leverage with a debt-to-equity ratio of 0.70.
StockPik's composite Value Score for ICCC is 64/100 — an above-average value rating. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
ICCC reports a moderate gross margin of 38.9% (sector average: 40.1%) and a modest operating margin of 4.4%.
ICCC shows revenue growing at 4% year-over-year, with earnings growing at 52%.